US 11,940,449 B2
Specific antigen sequences for COVID-19 and methods of use
Jyotsna S. Shah, Santa Clara, CA (US); Song Liu, San Jose, CA (US); Hari-Hara Potula, San Jose, CA (US); and Prerna Bhargava, Sunnyvale, CA (US)
Assigned to ID-Fish Technology, Inc., Milpitas, CA (US)
Filed by ID-Fish Technology, Inc., Milpitas, CA (US)
Filed on Feb. 11, 2022, as Appl. No. 17/669,979.
Claims priority of provisional application 63/149,998, filed on Feb. 16, 2021.
Prior Publication US 2022/0260586 A1, Aug. 18, 2022
Int. Cl. A61P 31/14 (2006.01); A61P 35/00 (2006.01); A61P 37/04 (2006.01); C07K 14/005 (2006.01); C07K 14/165 (2006.01); C07K 16/10 (2006.01); G01N 33/68 (2006.01)
CPC G01N 33/6854 (2013.01) [C07K 14/005 (2013.01); C12N 2770/20022 (2013.01); G01N 2333/165 (2013.01); G01N 2469/20 (2013.01); G01N 2800/26 (2013.01)] 17 Claims
 
1. A composition comprising at least four labelled and/or tagged and/or bound amino acid sequences, wherein the at least four labelled and/or tagged and/or bound amino acid sequences comprise amino acid sequences SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and variants thereof which retain the immunological binding profile of the corresponding non-variant.